ENDOCARDITIS

ENDOCARDITIS

Primary Disciplinary Field(s): Cardiology, Infectious Disease, Internal Medicine

1. Core Definition and Pathophysiology

Endocarditis is a severe and often life-threatening inflammatory disease specifically targeting the endocardium, the delicate, innermost lining of the heart chambers and the structures of the heart valves. The fundamental pathology, as highlighted in the source material, involves the inflammation of this lining and the associated valves, almost invariably triggered by an infectious process—primarily bacterial or, less commonly, fungal—a condition specifically termed Infective Endocarditis (IE). This condition represents a significant diagnostic and therapeutic challenge due to its capacity for rapid destruction of cardiac tissue and widespread systemic complications resulting from embolization.

The initiation of infective endocarditis typically requires two components: a compromised endocardial surface and the presence of microorganisms in the bloodstream (bacteremia). Pre-existing turbulent blood flow, often caused by structural heart defects, rheumatic heart disease, or degenerative valve changes, damages the smooth endothelial layer. This damage facilitates the local deposition of platelets and fibrin, forming a non-infected mass known as a sterile thrombus. When transient bacteremia occurs—for instance, following dental procedures, intravenous drug use, or infections elsewhere in the body—the circulating microorganisms adhere to and colonize this sterile clot.

Once colonized, the organisms multiply rapidly within this protected environment, embedding themselves in a matrix of platelets and fibrin that shields them from host immune defenses and circulating antibiotics. These pathological growths, known as vegetations, are the hallmark of IE. The vegetations lead to progressive tissue destruction, causing valve perforation or rupture of supporting structures (like chordae tendineae), resulting in acute valvular regurgitation. Furthermore, fragments of these friable vegetations can break off, leading to septic emboli that travel to various organs, including the brain, spleen, kidneys, and lungs, thereby transforming the localized heart infection into a critical systemic illness.

2. Classification and Types

Endocarditis is classified using several systems that guide clinical management, focusing on the speed of onset and the location of the infection. The distinction between acute and subacute forms dictates the urgency of intervention and often correlates with the virulence of the causative pathogen.

Acute Endocarditis is characterized by an abrupt onset, high fever, profound systemic toxicity, and rapid cardiac deterioration, often leading to severe hemodynamic compromise within days. This form is typically associated with highly virulent bacteria, such as Staphylococcus aureus, which can infect structurally normal heart valves and quickly erode tissue. In contrast, Subacute Endocarditis follows a more indolent course, developing over weeks or months, presenting with vague constitutional symptoms such as low-grade fever, malaise, and night sweats. Subacute forms are commonly caused by less aggressive organisms, such as Streptococci of the viridans group, and usually require pre-existing valvular damage to establish infection.

A second critical classification differentiates between the cardiac structure involved. Native Valve Endocarditis (NVE) occurs on the patient’s natural valves, while Prosthetic Valve Endocarditis (PVE) occurs on mechanical or bioprosthetic replacements. PVE carries a higher risk of complications and mortality due to the difficulty of eradicating infection from foreign material and is further divided into early PVE (occurring within 60 days post-surgery, usually due to perioperative contamination with aggressive pathogens) and late PVE (occurring after 60 days, often resembling NVE). Additionally, endocarditis can be categorized based on the side of the heart affected: left-sided endocarditis (aortic and mitral valves) is most common, leading to systemic emboli, while right-sided endocarditis (tricuspid valve) is frequently associated with intravenous drug use and typically causes septic pulmonary emboli.

3. Etiology and Risk Factors

The etiology of infective endocarditis is primarily microbial, relying on the presence of bacteremia combined with vulnerable cardiac anatomy. The profile of causative organisms has shifted over time, influenced by changes in healthcare practices and societal risk factors.

Historically, organisms like Streptococcus viridans, often introduced during dental procedures, were predominant. Today, Staphylococcus aureus is the most common pathogen, largely driven by the high incidence of healthcare-associated infections and the opioid epidemic resulting in increased intravenous drug use (IVDU). S. aureus is highly aggressive, frequently causing acute, destructive endocarditis. Other significant causes include coagulase-negative staphylococci (especially in prosthetic valve infections), enterococci (associated with genitourinary or gastrointestinal sources), and the fastidious HACEK group (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella), which typically cause subacute disease. Although rare, fungal endocarditis, caused primarily by Candida species, is associated with high mortality and affects immunocompromised patients or those with long-term central venous catheters.

Risk factors that predispose the endocardium to infection are numerous. The most significant anatomical risk factors include the presence of prosthetic heart valves or implanted cardiac devices (pacemakers/defibrillators). Native valve disease, such as previous rheumatic heart disease, degenerative calcific aortic stenosis, or congenital abnormalities like bicuspid aortic valve and ventricular septal defects, create the necessary turbulent flow. Lifestyle and medical factors leading to chronic or transient bacteremia greatly increase risk. These include poor dental hygiene, uncontrolled diabetes, chronic kidney disease requiring hemodialysis access, and, critically, intravenous drug use, which often bypasses normal cutaneous barriers and introduces large microbial loads directly into the venous system.

4. Clinical Manifestations and Systemic Effects

The clinical picture of endocarditis is highly variable, demanding a high index of suspicion from clinicians, particularly when constitutional symptoms are present without a clear source. Manifestations result from the systemic infection, the mechanical destruction of the heart valves, and the immunological response to the persistent bacterial load.

The most common initial presentation is fever, often accompanied by chills, profound fatigue, and generalized malaise—symptoms that can easily be mistaken for routine viral infections or other chronic conditions. A new or changed heart murmur is a critical physical finding, indicating the onset or worsening of valve regurgitation. As the disease progresses, signs of severe left-sided heart failure (dyspnea, pulmonary edema) may emerge rapidly due to acute aortic or mitral valve destruction, constituting a medical emergency.

Beyond cardiac symptoms, endocarditis frequently leads to systemic signs due to immune complex deposition or septic embolization. Embolism is a frequent and devastating complication, potentially affecting any organ. Neurological involvement is particularly common and dangerous, leading to ischemic strokes, transient ischemic attacks, or, if a mycotic aneurysm ruptures, intracerebral hemorrhage. Classic peripheral stigmata, though less frequently observed in modern acute presentations, include painful subcutaneous nodules (Osler’s nodes) on the fingers and toes, non-tender hemorrhagic spots (Janeway lesions) on the palms and soles, and characteristic retinal hemorrhages with pale centers (Roth spots). These manifestations reflect the underlying vasculitis and microemboli driven by the ongoing systemic infection.

5. Diagnosis and Management Principles

The definitive diagnosis of infective endocarditis relies on integrating clinical findings, consistent microbiology, and visualization of the vegetations. The gold standard diagnostic framework remains the Modified Duke Criteria, which organizes clinical data into major and minor categories to classify the likelihood of IE.

Major criteria include definitive echocardiographic evidence of endocardial involvement (such as oscillating intracardiac masses or abscess formation) or positive blood cultures showing typical organisms from multiple separate samples. Minor criteria encompass factors like fever, predisposing heart conditions, vascular phenomena (e.g., emboli), and immunologic phenomena. A confirmed diagnosis typically requires the satisfaction of two major criteria, one major and three minor criteria, or five minor criteria. Essential diagnostic steps begin with obtaining at least three sets of blood cultures drawn from different venipuncture sites over a short period, ideally before initiating empirical antibiotic therapy, to identify the causative organism and determine its antibiotic susceptibility profile.

Imaging studies are pivotal for diagnosis and monitoring. Transthoracic Echocardiography (TTE) is the initial, non-invasive imaging modality, useful for detecting larger vegetations and assessing overall cardiac function. However, when TTE is inconclusive, or if prosthetic valves or complex anatomy is involved, Transesophageal Echocardiography (TEE) is required. TEE provides superior resolution, allowing for precise visualization of smaller vegetations, micro-abscesses, pseudoaneurysms, and the extent of valve destruction—details crucial for guiding both medical and surgical management decisions.

6. Treatment and Surgical Indications

Treatment for infective endocarditis is intensive and requires prolonged courses of high-dose intravenous antibiotics, often administered in a hospital setting. The goal is to achieve total eradication of the pathogen sequestered within the vegetation, which necessitates highly bactericidal drugs given the protected nature of the infection.

Initial treatment is often empirical, targeting the most likely virulent organisms (e.g., S. aureus, Streptococci, Enterococci) based on clinical presentation and risk factors (e.g., community-acquired versus healthcare-associated). Once culture and susceptibility results are available, the regimen is streamlined to a pathogen-specific, targeted therapy. Typical treatment courses last 4 to 6 weeks. For sensitive organisms like Streptococci, regimens may involve penicillin or ceftriaxone, often combined with an aminoglycoside such as gentamicin for synergy. Vancomycin is the staple therapy for suspected or confirmed methicillin-resistant S. aureus (MRSA) infection. Careful monitoring of drug levels and renal function is necessary throughout the therapy.

Despite robust medical management, surgical intervention is necessary in nearly half of all IE cases. The primary indications for surgery are persistent or refractory heart failure caused by severe valvular regurgitation, uncontrolled infection despite optimal antibiotic therapy, and prevention of systemic embolization, particularly if large, mobile vegetations (typically greater than 10 mm) are present. Surgery involves thorough debridement of all infected and necrotic tissue, removal of vegetations, and repair or replacement of the damaged valve with a new prosthetic device. Prompt surgical consultation and intervention are critical in acute settings, as delayed surgery in the presence of severe heart failure significantly increases mortality risk.

7. Prevention and Prognosis

Preventive strategies for endocarditis focus primarily on prophylactic antibiotic administration for patients deemed to be at the highest risk of adverse outcomes from IE, particularly when undergoing procedures known to induce bacteremia.

Current professional guidelines have significantly restricted the indications for prophylactic antibiotics, reserving them exclusively for those patients most vulnerable to severe disease. This high-risk group includes individuals with prosthetic heart valves, those with a history of previous infective endocarditis, and specific congenital heart defects (e.g., unrepaired cyanotic heart disease). Prophylaxis is recommended only for dental procedures involving manipulation of the gingival tissue or the periapical region of the teeth, as these carry the greatest risk of high-level bacteremia. Prophylaxis is generally discouraged for routine gastrointestinal or genitourinary procedures unless an active infection is already present. Beyond pharmaceuticals, rigorous attention to hygiene, especially professional and personal dental care, is paramount for reducing the risk of transient bacteremia in all predisposed individuals.

The prognosis for infective endocarditis remains serious. Despite advances in antimicrobial therapy and surgical techniques, in-hospital mortality rates hover around 15% to 30%, increasing significantly if complications such as heart failure, stroke, or fungal etiology are present. Predictors of poor outcome include advanced age, involvement of the aortic valve, infection caused by S. aureus, and the development of severe perivalvular abscesses. Long-term surveillance involving regular clinical assessment and repeated echocardiography is required for survivors, as they face a persistent risk of recurrent IE and progressive deterioration of valve function, necessitating continued vigilance regarding prophylactic measures.

Further Reading

• CDC. Antibiotic Resistance & Threats.
• Mayo Clinic. Endocarditis: Symptoms & Causes.
• NCBI. Fungal Endocarditis: A Comprehensive Review.
• American Heart Association. Echocardiogram.